FULC · NASDAQ
Fulcrum Therapeutics (FULC) Stock Price & Fundamentals
Fulcrum Therapeutics (FULC) closed at $543.20 on Oct 9, 2026, down 0.41% from the previous close of $545.44.
Share price, past year
1Y +10.06%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $543.20 |
| Sep 30, 2026 | $555.79 |
| Aug 31, 2026 | $543.57 |
| Jul 31, 2026 | $509.72 |
| Jun 30, 2026 | $511.88 |
| May 29, 2026 | $529.84 |
| Apr 30, 2026 | $498.68 |
| Mar 31, 2026 | $507.78 |
| Feb 27, 2026 | $489.04 |
| Jan 30, 2026 | $496.68 |
| Dec 31, 2025 | $495.36 |
| Nov 28, 2025 | $471.28 |
| Oct 31, 2025 | $487.73 |
Key statistics
- Market cap
- $41.44B
- P/E (TTM)
- —
- EPS (TTM)
- −$1.21
- Revenue (TTM)
- —
- Net income (TTM)
- −$85.00M
- Shares outstanding
- 76.3M
- Dividend yield
- —
- 52-week range
- $464.58 – $567.21
Fulcrum Therapeutics's market cap is $41.44B, based on a share price of $543.20 and 76.3M shares outstanding as of Jun 30, 2026.
Financials
Fulcrum Therapeutics reported revenue of $0.00 for fiscal 2025, down 100.00% from fiscal 2024.
Fulcrum Therapeutics reported a net loss of $74.88M in fiscal 2025.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $0.00 | −100.0% | −$74.88M | — | −$1.18 | −$60.38M |
| FY2024ended Dec 31, 2024 | $80.00M | +2,752.1% | −$9.73M | −12.2% | −$0.16 | −$2.50M |
| FY2023ended Dec 31, 2023 | $2.81M | −55.8% | −$97.34M | −3,470.1% | −$1.59 | −$91.47M |
| FY2022ended Dec 31, 2022 | $6.34M | −66.9% | −$109.87M | −1,732.4% | −$2.44 | −$99.01M |
| FY2021ended Dec 31, 2021 | $19.16M | +117.2% | −$80.85M | −421.9% | −$2.29 | −$80.19M |
| FY2020ended Dec 31, 2020 | $8.82M | — | −$70.82M | −802.7% | −$2.79 | −$55.00M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q3 FY2025ended Sep 30, 2025 | $0.00 | −$19.60M | −$0.31 |
| Q2 FY2025ended Jun 30, 2025 | $0.00 | −$17.30M | −$0.28 |
| Q4 FY2024ended Dec 31, 2024 | $0.00 | −$16.57M | −$0.25 |
| Q3 FY2024ended Sep 30, 2024 | $0.00 | −$21.70M | −$0.35 |
| Q2 FY2024ended Jun 30, 2024 | $80.00M | — | — |
| Q1 FY2024ended Mar 31, 2024 | $0.00 | — | — |
| Q4 FY2023ended Dec 31, 2023 | $871.00K | — | — |
| Q3 FY2023ended Sep 30, 2023 | $759.00K | — | — |
Company profile
- Name
- Fulcrum Therapeutics, Inc.
- Ticker
- FULC
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- 26 Landsdowne Street, Cambridge, MA 02139
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0001680581
Recent SEC filings
- Aug 17, 2026
- Aug 10, 2026
- Jul 30, 2026
- Jun 25, 2026
- Jun 11, 2026
- Jun 4, 2026
- Jun 1, 2026
- Apr 27, 2026
Frequently asked questions
What is Fulcrum Therapeutics's stock price?
Fulcrum Therapeutics (FULC) closed at $543.20 on Oct 9, 2026, down 0.41% from the previous close of $545.44.
What is Fulcrum Therapeutics's market cap?
Fulcrum Therapeutics's market cap is $41.44B, based on a share price of $543.20 and 76.3M shares outstanding as of Jun 30, 2026.
How much revenue does Fulcrum Therapeutics make?
Fulcrum Therapeutics reported revenue of $0.00 for fiscal 2025, down 100.00% from fiscal 2024.
Does Fulcrum Therapeutics pay a dividend?
Fulcrum Therapeutics's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Fulcrum Therapeutics, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures